FRE Firebrick Pharma Limited
Healthcare · Drug Manufacturers - General
· website
$0.03
52wk 0.02 – 0.07
Overall
59.0
Value
58.1
Growth
100.0
Health
100.0
Quality
0.0
Momentum
9.6
Dividend
—
Price
About Firebrick Pharma Limited
Firebrick Pharma Limited develops and commercializes povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal and throat spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.
Price analytics
Returns
| 1 day | 0.0% |
| 1 week | 7.7% |
| 1 month | -12.5% |
| 3 months | -15.2% |
| 6 months | -55.6% |
| 1 year | -58.8% |
| 3 years | -22.2% |
Risk
| Volatility (1y ann.) | 90.6% |
| Beta vs ASX 200 | -0.21 |
| Sharpe (1y) | -0.58 |
| VaR 95% (1-day) | -9.1% |
| Max drawdown (1y) | -65.7% |
| Off 1-year high | -60.0% |
Technicals
| RSI(14) | 40 |
| vs 50DMA | -2.5% |
| vs 200DMA | -38.3% |
| Trend | Death cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
58.1
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
46
Price / Sales
0
Growth
100.0
Revenue growth (1y)
100
Revenue CAGR (3y)
100
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
100.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
100
Debt / Equity
—
Quality (Profitability & Cash Flow)
0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
9.6
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
38
Position in 52-week range
8
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$8.04M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.01
Dividend yield
—
Payout ratio
0.0%
Beta
0.85
EV / EBITDA
-2.25
Price / Book
4.67
ROE
-189.2%
Operating margin
-4,041.5%
Net margin
0.0%
Total cash
$1.32M
Total debt
$0
Current ratio
3.85
Debt / Equity
—
Free cash flow
$-1.47M
Avg volume
140,643
Latest annual results
(FY ending 30 Jun 2025)
- Revenue$293.42K
- Gross profit$104.82K
- Operating income-$2.87M
- Net income-$2.63M
- Diluted EPS-0.01
- Free cash flow-$1.86M
- Net debt-$983.35K